New Composite Part Nomination
What is PanoPOLY?
Pancreatic cancer remains one of the most lethal and challenging cancers to treat, primarily due to late diagnosis and drug resistance. We, PanoPOLY, aim to tackle this issue by developing a novel dual-targeting nanobody using a synthetic biology approach to suppress the tumor growth and overcome resistance to gemcitabine, the standard chemotherapy for pancreatic cancer.
Read moreThe Need for Targeted Therapies
Conventional treatments like surgery, chemotherapy, and radiotherapy face limitations, primarily due to the aggressive nature of pancreatic cancer and its resistance to drugs. The lack of targeted therapies underscores the urgent need for innovative approaches to improve treatment efficacy and patient survival.
About Our Project
We have developed a dual-targeting nanobody, designated Panobody,which simultaneously targets two critical receptors: EGFR and HER2. These receptors have been observed to be overexpressed in pancreatic cancers and exhibit further increased expression upon the development of acquired resistance to gemcitabine. With the development of Panobody, we aim to specifically inhibit tumour growth and enhance chemotherapy's effectiveness, thereby improving patient survival rates.
Our Mission
To offer new treatment strategies for cancer therapies
PanoPOLY is committed to pioneering new strategies for pancreatic cancer treatment. Through cutting-edge synthetic biology and collaboration with experts, we aspire to bring hope to patients and significantly impact the landscape of cancer therapy.
Dual-Targeting Nanobody
Panobody simultaneously targets EGFR & HER2
These critical receptors have been observed to be overexpressed in pancreatic cancers and exhibit further increased expression upon the development of acquired resistance to gemcitabine. With the development of Panobody, we aim to specifically inhibit tumour growth and enhance chemotherapy's effectiveness, thereby improving patient survival rates.
Advantages
It offers flexibility and novelty
Panobody offers unmatched advantages in treating pancreatic cancer. Its flexible design, small size, low production cost, and better cell penetration enable precise targeting of overexpressed receptors, inhibiting tumor growth and enhancing chemotherapy's effectiveness, ultimately improving patient survival rates and revolutionizing cancer treatment.
Panoramic Action, Polymeric Innovation
Our Promotion Video
-
ExperimentsCheck out our lab journey -
-
Human PracticesCheck out our human practices page -
EducationExplore our education page -
